Prospera Financial Services Inc reduced its position in shares of Trovagene Inc. (NASDAQ:TROV) by 0.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 157,625 shares of the company’s stock after selling 500 shares during the period. Prospera Financial Services Inc’s holdings in Trovagene were worth $714,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Bridger Management LLC acquired a new position in Trovagene during the first quarter worth $15,301,000. Geode Capital Management LLC raised its position in Trovagene by 1.3% in the first quarter. Geode Capital Management LLC now owns 183,442 shares of the company’s stock worth $853,000 after buying an additional 2,363 shares during the period. State Street Corp raised its position in Trovagene by 21.3% in the first quarter. State Street Corp now owns 390,759 shares of the company’s stock worth $1,819,000 after buying an additional 68,557 shares during the period. BlackRock Institutional Trust Company N.A. raised its position in Trovagene by 6.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 660,640 shares of the company’s stock worth $3,072,000 after buying an additional 40,100 shares during the period. Finally, Princeton Capital Management Inc. acquired a new position in Trovagene during the second quarter worth $314,000. 31.06% of the stock is owned by hedge funds and other institutional investors.
Shares of Trovagene Inc. (NASDAQ:TROV) traded up 1.06% during mid-day trading on Thursday, hitting $4.77. 144,646 shares of the stock were exchanged. The stock’s market cap is $143.80 million. Trovagene Inc. has a 12 month low of $2.85 and a 12 month high of $7.18. The company has a 50-day moving average price of $5.14 and a 200-day moving average price of $5.01.
Trovagene (NASDAQ:TROV) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by $0.03. Trovagene had a negative net margin of 8,495.00% and a negative return on equity of 80.13%. Equities analysts expect that Trovagene Inc. will post ($1.34) earnings per share for the current year.
TROV has been the subject of a number of recent research reports. Maxim Group initiated coverage on shares of Trovagene in a report on Wednesday, July 6th. They issued a “buy” rating and a $12.00 target price for the company. Zacks Investment Research raised shares of Trovagene from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a report on Wednesday. Piper Jaffray Cos. set a $4.00 price objective on shares of Trovagene and gave the stock a “hold” rating in a research note on Friday, August 5th. Finally, Cantor Fitzgerald raised shares of Trovagene from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $5.00 to $7.00 in a research note on Monday, August 8th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $7.04.
Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.
Want to see what other hedge funds are holding TROV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trovagene Inc. (NASDAQ:TROV).
Receive News & Ratings for Trovagene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trovagene Inc. and related companies with MarketBeat.com's FREE daily email newsletter.